Obnyx 40mg Capsule

Obnyx 40mg Capsule is used for the treatment of Prostate cancer and other conditions that may be applicable. Enzalutamide It works by blocking testosterone and other male hormones.

Uses of Obnyx 40mg Capsule:

• Metastatic castration-resistant prostate cancer.
• Non-metastatic castration-resistant prostate cancer.

How does the Obnyx 40mg Capsule work?

Enzalutamide is an androgen receptor inhibitor. It works by blocking male hormones, or androgens, such as testosterone, from acting on the prostate cancer cells which stops them from growing and multiplying.

How to Use & Dosage

It is usually taken orally, usually once every day. Capsules should be swallowed whole, not chewed or opened, and may be taken with or without meals.

Take enzalutamide with or without your other prostate cancer medicines, such as degarelix or leuprolide. For more information, ask your doctor or pharmacist for the manufacturer’s patient information.

Possible Side Effects:

• Fatigue
• Nausea
• Vomiting
• Fever
• Hot flashes
• Hypertension
• Diarrhea
• Nausea
• Seizures

Safety Advise:

🫘 Kidney

Obnyx 40 mg capsules should be used cautiously in patients with renal disease. Dosage may need to be adjusted. Be sure to consult your health care provider.

🟤 Liver

Obnyx Capsule should be used with caution in patients with severe liver disease. Dosage may have to be changed. Please talk to your health care provider.

🤰 Pregnancy

Obnyx 40 mg capsules may be unsafe to use during pregnancy. Discuss with your health care provider.

🤱 Breast Feeding

There is no information available on the use of the Obnyx 40 mg capsule during breastfeeding. You should speak to your health care provider.

🍷 Alcohol

It is not known if Obnyx 40 mg capsule is safe to take when drinking alcohol. Please talk to your healthcare provider

Storage Instructions:

Store in a cool, dry place.

References:

Tripathi KD. Essentials of Medical Pharmacology. 9th ed. New Delhi: Jaypee Brothers Medical Publishers.

Katzung BG, Vanderah TW. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill.

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine. 2012;367(13):1187-1197.

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine. 2014;371(5):424-433.

Rathkopf DE, Scher HI. Apalutamide, darolutamide and enzalutamide for non-metastatic castration-resistant prostate cancer: a comparative review. Drugs. 2018;78(11):1149-1156

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.